시장보고서
상품코드
1416121

세계의 파브리병 치료제 시장(2024-2028년)

Global Fabry Disease Drugs Market 2024-2028

발행일: | 리서치사: TechNavio | 페이지 정보: 영문 149 Pages | 배송안내 : 즉시배송

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

개요

파브리병 치료제 시장은 2023년부터 2028년에 걸쳐 8억 5,906만 달러 확대되고, 예측 기간 중 연평균 복합 성장률(CAGR)은 7.43%를 나타낼 것으로 예측됩니다.

파브리병 치료제 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공합니다. 희귀질환 이환율 상승, 희소 의약품 개발에 대한 장려 조치 이용 가능성, 연구개발 주력과 FDA의 파브리병 치료제 인가 확대 등에 의해 시장 성장이 촉진되고 있습니다.

시장 범위
기준년 2024년
종료년 2028년
예측 기간 2024-2028년
성장 모멘텀 가속
YOY 2024 6.83%
CAGR 7.43%
증분액 8억 5,906만 달러

본 조사에서는 향후 몇 년간 파브리병 치료제 시장 성장을 가속하는 주요인 중 하나로서 전략적 제휴나 파트너십 주력을 들고 있습니다. 세계 파브리병 치료제 시장의 지정학적인 불확실성, 파브리병에 대한 계몽 활동 증가는 시장의 높은 수요로 연결될 것입니다.

목차

제1장 주요 요약

  • 시장 개요

제2장 시장 구도

  • 시장 생태계

제3장 시장 규모

  • 시장의 정의
  • 시장 부문 분석
  • 시장 규모(2023년)
  • 시장 전망(2023-2028년)

제4장 시장 규모 실적

  • 세계의 파브리병 치료제 시장(2018-2022년)
  • 유통 채널별 부문 분석(2018-2022년)
  • 투여 경로별 부문 분석(2018-2022년)
  • 지역별 부문 분석(2018-2022년)
  • 국가별 부문 분석(2018-2022년)

제5장 Five Forces 분석

  • Five Forces 요약
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 신규 진출업체의 위협
  • 대체품의 위협
  • 경쟁 위협
  • 시장 현황

제6장 시장 세분화 : 유통 채널별

  • 시장 부문
  • 비교 : 유통 채널별
  • 병원 약국 : 시장 규모와 예측(2023-2028년)
  • 소매 약국 : 시장 규모와 예측(2023-2028년)
  • 온라인 약국 : 시장 규모와 예측(2023-2028년)
  • 시장 기회 : 유통 채널별

제7장 시장 세분화 : 투여 경로별

  • 시장 부문
  • 비교 : 투여 경로별
  • 정맥 경로 : 시장 규모와 예측(2023-2028년)
  • 경구 : 시장 규모와 예측(2023-2028년)
  • 시장 기회 : 투여 경로별

제8장 고객 상황

  • 고객 상황 개요

제9장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 : 시장 규모와 예측(2023-2028년)
  • 유럽 : 시장 규모와 예측(2023-2028년)
  • 아시아 : 시장 규모와 예측(2023-2028년)
  • 세계 기타 지역 : 시장 규모와 예측(2023-2028년)
  • 미국 : 시장 규모와 예측(2023-2028년)
  • 중국 : 시장 규모와 예측(2023-2028년)
  • 독일 : 시장 규모와 예측(2023-2028년)
  • 영국 : 시장 규모와 예측(2023-2028년)
  • 일본 : 시장 규모와 예측(2023-2028년)
  • 시장 기회 : 지역 상황별

제10장 성장 촉진요인, 과제 및 동향

  • 시장 성장 촉진요인
  • 시장이 해결해야 할 과제
  • 성장 촉진요인과 과제의 영향
  • 시장 동향

제11장 벤더 구도

  • 개요
  • 벤더 구도
  • 혼란 상황
  • 업계 리스크

제12장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • 4D Molecular Therapeutics Inc.
  • Amicus Therapeutics Inc.
  • CHIESI Farmaceutici SpA
  • Freeline Therapeutics Holdings plc
  • Idorsia Pharmaceuticals Ltd.
  • Sangamo Therapeutics Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.

제13장 부록

LSH 24.01.31

Abstract

The fabry disease drugs market is forecasted to grow by USD 859.06 mn during 2023-2028, accelerating at a CAGR of 7.43% during the forecast period. The report on the fabry disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of rare diseases, availability of incentives for development of orphan drugs, and growing focus on research and development and FDA approval of fabry disease drugs.

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20246.83%
CAGR7.43%
Incremental Value$859.06mn

Technavio's fabry disease drugs market is segmented as below:

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Route Of Administration

  • Intravenous route
  • Oral route

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the focus on strategic alliances and partnerships as one of the prime reasons driving the fabry disease drugs market growth during the next few years. Also, geopolitical uncertainties in global fabry disease drugs market and growing number of awareness programs for fabry disease will lead to sizable demand in the market.

The report on the fabry disease drugs market covers the following areas:

  • Fabry disease drugs market sizing
  • Fabry disease drugs market forecast
  • Fabry disease drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading fabry disease drugs market vendors that include 4D Molecular Therapeutics Inc., Amicus Therapeutics Inc., CHIESI Farmaceutici SpA, Freeline Therapeutics Holdings plc, Idorsia Pharmaceuticals Ltd., Sangamo Therapeutics Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.. Also, the fabry disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

  • 4.1 Global fabry disease drugs market 2018 - 2022
  • Exhibit 18: Historic Market Size - Data Table on global fabry disease drugs market 2018 - 2022 ($ million)
  • 4.2 Distribution Channel Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
  • 4.3 Route Of Administration Segment Analysis 2018 - 2022
  • Exhibit 20: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ million)
  • 4.4 Geography Segment Analysis 2018 - 2022
  • Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
  • 4.5 Country Segment Analysis 2018 - 2022
  • Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Distribution Channel

  • 6.1 Market segments
  • Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
  • Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
  • 6.2 Comparison by Distribution Channel
  • Exhibit 32: Chart on Comparison by Distribution Channel
  • Exhibit 33: Data Table on Comparison by Distribution Channel
  • 6.3 Hospital pharmacies - Market size and forecast 2023-2028
  • Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
  • 6.4 Retail pharmacies - Market size and forecast 2023-2028
  • Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • 6.5 Online pharmacies - Market size and forecast 2023-2028
  • Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
  • Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • 6.6 Market opportunity by Distribution Channel
  • Exhibit 46: Market opportunity by Distribution Channel ($ million)
  • Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Route of Administration

  • 7.1 Market segments
  • Exhibit 48: Chart on Route of Administration - Market share 2023-2028 (%)
  • Exhibit 49: Data Table on Route of Administration - Market share 2023-2028 (%)
  • 7.2 Comparison by Route of Administration
  • Exhibit 50: Chart on Comparison by Route of Administration
  • Exhibit 51: Data Table on Comparison by Route of Administration
  • 7.3 Intravenous route - Market size and forecast 2023-2028
  • Exhibit 52: Chart on Intravenous route - Market size and forecast 2023-2028 ($ million)
  • Exhibit 53: Data Table on Intravenous route - Market size and forecast 2023-2028 ($ million)
  • Exhibit 54: Chart on Intravenous route - Year-over-year growth 2023-2028 (%)
  • Exhibit 55: Data Table on Intravenous route - Year-over-year growth 2023-2028 (%)
  • 7.4 Oral route - Market size and forecast 2023-2028
  • Exhibit 56: Chart on Oral route - Market size and forecast 2023-2028 ($ million)
  • Exhibit 57: Data Table on Oral route - Market size and forecast 2023-2028 ($ million)
  • Exhibit 58: Chart on Oral route - Year-over-year growth 2023-2028 (%)
  • Exhibit 59: Data Table on Oral route - Year-over-year growth 2023-2028 (%)
  • 7.5 Market opportunity by Route of Administration
  • Exhibit 60: Market opportunity by Route of Administration ($ million)
  • Exhibit 61: Data Table on Market opportunity by Route of Administration ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • 9.2 Geographic comparison
  • Exhibit 65: Chart on Geographic comparison
  • Exhibit 66: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
  • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • 9.4 Europe - Market size and forecast 2023-2028
  • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • 9.5 Asia - Market size and forecast 2023-2028
  • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • 9.7 US - Market size and forecast 2023-2028
  • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
  • 9.8 China - Market size and forecast 2023-2028
  • Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ million)
  • Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
  • Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)
  • 9.9 Germany - Market size and forecast 2023-2028
  • Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • 9.10 UK - Market size and forecast 2023-2028
  • Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • 9.11 Japan - Market size and forecast 2023-2028
  • Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
  • Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
  • Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
  • Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 103: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 105: Impact of drivers and challenges in 2023 and 2028
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 107: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 109: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 110: Matrix on vendor position and classification
  • 12.3 4D Molecular Therapeutics Inc.
  • Exhibit 111: 4D Molecular Therapeutics Inc. - Overview
  • Exhibit 112: 4D Molecular Therapeutics Inc. - Product / Service
  • Exhibit 113: 4D Molecular Therapeutics Inc. - Key offerings
  • 12.4 Amicus Therapeutics Inc.
  • Exhibit 114: Amicus Therapeutics Inc. - Overview
  • Exhibit 115: Amicus Therapeutics Inc. - Product / Service
  • Exhibit 116: Amicus Therapeutics Inc. - Key offerings
  • 12.5 CHIESI Farmaceutici SpA
  • Exhibit 117: CHIESI Farmaceutici SpA - Overview
  • Exhibit 118: CHIESI Farmaceutici SpA - Product / Service
  • Exhibit 119: CHIESI Farmaceutici SpA - Key offerings
  • 12.6 Freeline Therapeutics Holdings plc
  • Exhibit 120: Freeline Therapeutics Holdings plc - Overview
  • Exhibit 121: Freeline Therapeutics Holdings plc - Product / Service
  • Exhibit 122: Freeline Therapeutics Holdings plc - Key offerings
  • 12.7 Idorsia Pharmaceuticals Ltd.
  • Exhibit 123: Idorsia Pharmaceuticals Ltd. - Overview
  • Exhibit 124: Idorsia Pharmaceuticals Ltd. - Product / Service
  • Exhibit 125: Idorsia Pharmaceuticals Ltd. - Key offerings
  • 12.8 Sangamo Therapeutics Inc.
  • Exhibit 126: Sangamo Therapeutics Inc. - Overview
  • Exhibit 127: Sangamo Therapeutics Inc. - Product / Service
  • Exhibit 128: Sangamo Therapeutics Inc. - Key offerings
  • 12.9 Sanofi SA
  • Exhibit 129: Sanofi SA - Overview
  • Exhibit 130: Sanofi SA - Business segments
  • Exhibit 131: Sanofi SA - Key news
  • Exhibit 132: Sanofi SA - Key offerings
  • Exhibit 133: Sanofi SA - Segment focus
  • 12.10 Takeda Pharmaceutical Co. Ltd.
  • Exhibit 134: Takeda Pharmaceutical Co. Ltd. - Overview
  • Exhibit 135: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 136: Takeda Pharmaceutical Co. Ltd. - Key news
  • Exhibit 137: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 138: Inclusions checklist
  • Exhibit 139: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 140: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 141: Research methodology
  • Exhibit 142: Validation techniques employed for market sizing
  • Exhibit 143: Information sources
  • 13.5 List of abbreviations
  • Exhibit 144: List of abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제